Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
about
Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasQuantification of HER family receptors in breast cancerDetection of SYT and EWS gene rearrangements by dual-color break-apart CISH in liquid-based cytology samples of synovial sarcoma and Ewing sarcoma/primitive neuroectodermal tumor.Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort studyRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplificationAndrogen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events.High-resolution, high-throughput, positive-tone patterning of poly(ethylene glycol) by helium beam exposure through stencil masksHybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsUpdate on HER2 testing for breast and upper gastrointestinal tract cancers.HER2 assessment by silver in situ hybridization: where are we now?Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.Helium beam shadowing for high spatial resolution patterning of antibodies on microstructured diagnostic surfaces.Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing.Tissue Microarray Technology for Molecular Applications: Investigation of Cross-Contamination between Tissue Samples Obtained from the Same Punching Device.The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.HER2 assessment in locally advanced gastric cancer: comparing the results obtained with the use of two primary tumour blocks versus those obtained with the use of all primary tumour blocks.HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH).Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.
P2860
Q26865068-45A4094A-2515-4D20-8079-9B0522A95F98Q27015506-3FF5C542-1F1E-4CBE-9A38-36E210AF6703Q33641011-76AFBFCF-407E-4699-B9F5-73397DD0BE40Q33758934-CED5F9FB-6984-4E94-A699-13C1B12CD2E0Q33862786-13A42207-9D37-48B8-9DC7-982EA6339FE8Q34084063-2E8640E8-7CD5-4CAF-869B-64A27406D793Q34218734-ED339A4C-EEB6-41DD-A2FC-2D725FFB6D9BQ34743809-F21996AB-33AB-444C-8BB4-C2A47135D92CQ35195417-26338090-2F06-4989-B14D-0B5B72EBB090Q35660389-B5715271-895E-4E91-8C08-4F746E19E667Q35670454-946DA59F-A884-435D-B73F-560F02B37506Q36107134-0A9169BF-DD71-4AA5-8372-1A1211577F49Q37075632-9B630CC1-77D7-4A9B-A8AB-FFF919C43B35Q37886993-611F99A4-74F6-47D1-8003-938BF45B9ECAQ38314355-257ADB27-8E57-4791-BDE8-36EB9F99B16CQ38394606-3D858D80-0633-4E4B-A451-BA95AC2BF88AQ38412375-EF1D2A61-06A0-4826-B91D-A06EC7A663D6Q38612634-0F762B73-12CD-4D8B-BA36-B417E5436EDAQ38980438-E2511095-0559-444B-8D6B-1F0240980FBEQ40161149-ADCC2BA7-588F-4937-A130-BB5FF7A2C79DQ40402965-EFFA12E5-F12E-4A05-A206-104621E5BEC8Q46431111-EDA6653D-9DE9-4CF2-8770-7A0D776ED825Q48132295-A5C7EB13-3909-4B8A-9B69-DEE9E3FB432FQ53158559-34A9FB5E-408F-4977-8DA6-583D394E71D1Q54518974-F353A32E-158A-4C69-ADB8-84F3827EEC05
P2860
Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Bright-field in situ hybridiza ...... methods with patient outcome.
@en
Bright-field in situ hybridiza ...... orrelation between chromogenic
@nl
type
label
Bright-field in situ hybridiza ...... methods with patient outcome.
@en
Bright-field in situ hybridiza ...... orrelation between chromogenic
@nl
prefLabel
Bright-field in situ hybridiza ...... methods with patient outcome.
@en
Bright-field in situ hybridiza ...... orrelation between chromogenic
@nl
P2093
P1476
Bright-field in situ hybridiza ...... ) methods with patient outcome
@en
P2093
Geoffrey F Beadle
Glenn D Francis
Sandra R Stein
P356
10.1097/PDM.0B013E31816F6374
P50
P577
2009-06-01T00:00:00Z